Abstract 1685P
Background
Family caregivers play a vital role in cancer care, yet their effective integration, needs assessment, and support in German outpatient settings require further examination. This qualitative study explores family caregivers' experiences, preferences, and integration challenges, employing a unique dyadic approach to analyze patient-caregiver dynamics and incorporating oncologists' perspectives on effective caregiver integration. It also suggests areas of potential integration of innovative technologies to address these challenges.
Methods
The study uses a reflexive thematic analysis of qualitative semi-structured interviews with 15 patient-caregiver dyads involving advanced cancer patients with solid tumours and three oncologists at a German outpatient cancer centre.
Results
Three interconnected themes emerged: 1) The multifaceted impact of illness on patient-caregiver dyads, emphasizing the significance of dyadic support and incongruence; 2) Communication with physicians and understanding of healthcare Information, stressing the need for tailored prognostic communication, and considering health literacy aspects; 3) Navigating healthcare services and psychosocial support, underlining the importance of a regular needs and distress evaluation, providing personalized support in the form of a referral and proactive guidance upon cancer diagnosis.
Conclusions
The study's findings have practical implications for healthcare practice and policy. Healthcare systems should adopt a more caregiver-inclusive approach that provides proactive psychosocial support at the beginning of the cancer journey, and tailored communication with healthcare professionals. This approach could include developing and implementing targeted digital tools that allow automated needs evaluation and incorporation of referrals for specialized support programs for cancer caregivers. The future investigation and implementation of such innovative technologies is important, as they have the potential to reduce the caregiving burden and significantly enhance the overall quality of cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Rose: Other, Institutional, Leadership Role: Head of Promis National Center Germany. All other authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11